8-KShareholder Matters

ELI LILLY & Co 8-K Report, Shareholder Vote Results (May 8, 2018)

Filed May 8, 2018For Securities:LLY

Summary

This 8-K filing from Eli Lilly and Company reports the voting results from their annual shareholder meeting held on May 7, 2018. The key outcomes include the re-election of five director nominees for three-year terms, and overwhelming approval for the appointment of Ernst & Young as the principal independent auditor, as well as the advisory vote on executive compensation and the Amended and Restated 2002 Lilly Stock Plan. While these were significant approvals, investors should note that two proposals seeking to amend the Articles of Incorporation – one to eliminate the classified board structure and another to eliminate supermajority voting provisions – did not achieve the required 80% of outstanding shares for approval. Several shareholder proposals on topics such as cannabis descheduling, political contributions, animal laboratories, and drug pricing linked to executive compensation were also voted down by a significant margin.

Key Highlights

  • 1Five director nominees were successfully elected to serve three-year terms ending in 2021, indicating continued shareholder confidence in the current board.
  • 2Shareholders overwhelmingly approved the appointment of Ernst & Young as the principal independent auditor, a routine but important vote for corporate governance.
  • 3An advisory vote on executive compensation received strong shareholder support, with a significant majority voting in favor.
  • 4The Amended and Restated 2002 Lilly Stock Plan was approved by shareholders, reflecting support for the company's equity-based compensation strategies.
  • 5Proposals to eliminate the classified board structure and supermajority voting provisions did not pass, requiring an 80% vote of outstanding shares, suggesting a preference for maintaining the existing governance framework among a substantial portion of shareholders.
  • 6Multiple shareholder proposals, including those on cannabis, political contributions, animal laboratories, and drug pricing linked to compensation, were not approved by a significant margin.

Frequently Asked Questions

The meeting resulted in the re-election of all five director nominees, ratification of Ernst & Young as independent auditor, and approval of an advisory vote on executive compensation and the Lilly Stock Plan. However, proposals to eliminate the classified board and supermajority voting provisions did not meet the required 80% threshold for approval.

No, all shareholder proposals presented at the meeting, including those related to cannabis, political contributions, animal laboratories, and drug pricing and compensation, were not approved by the shareholders.

The failure of the proposals to eliminate the classified board structure and supermajority voting provisions indicates that a significant portion of shareholders either prefer the existing governance structure or did not find the proposed changes compelling enough to warrant the required 80% approval from outstanding shares.

Shareholders approved the executive compensation through an advisory vote, with a large majority voting in favor, signaling general support for the company's compensation practices for its named executive officers.